Table 1 Table 1
| Â | case1 | case2 |
|---|---|---|
General information | Â | Â |
age | 73 | 90 |
sex | Male | Male |
vaccination status | NV | NV |
preexisting condition | CKD stage 4 Hypertension Diabetes Coronary Disease | Hypertension Atrial Fibrillation |
severity of COVID-19 | critical | critical |
BMI(kg/m2) | 28.3 | 20.2 |
Onset and Progress | Â | Â |
Date of onset | 2021/12/21 | 2021/12/17 |
Date of entering ICU | 2022/1/4 | 2022/1/1 |
Duration between onset and entering ICU(d) | 13 | 15 |
Days of invasive mechanical ventilation(d) | 9 | >28 |
Days of renal replacement therapy(d) | >28 | / |
Anticoagulation Therapy | Â | Â |
Date of starting anticoagulants | 2022/1/4 | 2022/1/1 |
Date of hematoma or hemorrhage | 2022/1/21 | 2022/2/7 |
Duration between starting anticoagulation and first bleeding event(d) | 18 | 37 |
Initial dose | LMWHs (2500 IU q12h) | LMWHs (2500 IU q12h) |
Dosage at hematoma or bleeding | LMWHs (7500 IU q12h) | Nadroparin Calcium (3264 IU qd) |
Sites of hematoma or bleeding | hepatic hemorrhage retroperitoneal hematoma(right) iliopsoas hematoma(right) gastrointestinal tract | scapula muscular hematoma(left) retroperitoneal hematoma(left) gastrointestinal tract |
Interventions | 1.TAE 2.anticoagulation suspended 3.nafamostat mesilate | anticoagulation suspended |
Cumulative days of anticoagulation therapy(d) | 28 | 29 |
Cumulative days of suspending anticoagulation(d) | 11 | 6 |
Transfusion | Â | Â |
RBC(u) | 16 | 16 |
Platelet(u) | 20 | / |
Plasma(ml) | 1200 | 800 |
Outcomes | Alive | Died |